CRO

Market Access

The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.

News

Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose their jobs in a bid to cut €75m in costs.

Patients

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

R&D

Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.

Sales & Marketing

Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO to streamline drug development.

News

Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations